Kelly, W., Danila, D., Lin, C.-C., Lee, J.-L., Matsubara, N., Ward, P., … Appleman, L. J. (2023). 1765O Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). In Annals of Oncology (Vol. 34, pp. S953–S954). Elsevier BV. https://doi.org/10.1016/j.annonc.2023.09.2715

Kelly, W., D. Danila, C. -. C. Lin, J. -. L. Lee, N. Matsubara, P. Ward, A. J. Armstrong, et al. “1765O Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).” In Annals of Oncology, 34:S953–54. Elsevier BV, 2023. https://doi.org/10.1016/j.annonc.2023.09.2715.

Kelly W, Danila D, Lin C-C, Lee J-L, Matsubara N, Ward P, et al. 1765O Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). In: Annals of Oncology. Elsevier BV; 2023. p. S953–4.

Kelly, W., et al. “1765O Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).” Annals of Oncology, vol. 34, Elsevier BV, 2023, pp. S953–54. Crossref, doi:10.1016/j.annonc.2023.09.2715.

Kelly W, Danila D, Lin C-C, Lee J-L, Matsubara N, Ward P, Armstrong AJ, Pook D, Kim M, Dorff T, Fischer S, Lin Y-C, Horvath LG, Sumey C, Yang Z, Jurida G, Connarn J, Penny H, Stieglmaier J, Appleman LJ. 1765O Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. Elsevier BV; 2023. p. S953–S954.